Sean Stalfort

Sean Stalfort was the founder of Benevolent Capital Partners LLC (Private Equity), founded in 2005, where the title held was Founding Partner from 2005 to 2010.
Mr. Stalfort is the founder of PBM Capital Group LLC, founded in 2010, holding the titles of Chairman and CEO since 2010.
Current jobs include Director at PBM Pharmaceuticals, Inc., Tolerion, Inc., Xalud Therapeutics, Inc., Verrica Pharmaceuticals, Inc. (since 2015), SalioGen Therapeutics, Inc., Baxis Pharmaceuticals, Inc., Vetana Animal Health, Inc., and Partner at Octagon Partners LLC and Octagon Finance LLC.
Also holds positions as Board of Directors at Novartis Gene Therapies Switzerland GmbH, Independent Director at Taysha Gene Therapies, Inc. (since 2023), Independent Director at Acumen Pharmaceuticals, Inc. (since 2018).
Former jobs include Director at Perrigo Co., Genapure Corp., Candel Therapeutics, Inc., Quantapore, Inc., and PBM Products LLC (Executive Vice President-New Business Development).
Director at Dova Pharmaceuticals, Inc. from 2016 to 2019.
Senior Underwriter at NatWest Markets Securities, Inc. in 2004.
Vice President at Greenwich Capital Holdings, Inc. in 1996.
Investment Banking Associate at CS First Boston Pacific, Inc. in 1992.
Senior Vice President-Capital Markets at Enterprise Mortgage Acceptance Co. LLC.
Senior Vice President at Koch Financial Corp.
Founding Partner at Ravelin Capital Group LLC.
Education includes undergraduate degree from Brown University in 1991 and undergraduate studies at the University of Massachusetts.